Researchers published integrated methods for simultaneous, multiplexed epigenetic and genetic programming of primary human T cells, showcasing a platform that can stably silence or activate multiple genes without making permanent DNA cuts. The work, reported in Nature Biotechnology and linked publications, couples CRISPRoff/CRISPRon‑style epigenetic tools with multiplex editing to create T cells with enhanced resistance, activity and tumor functionality. Teams from the Arc Institute, Gladstone Institutes and UCSF demonstrated durable reprogramming that improves T‑cell phenotypes relevant to cancer therapy, potentially reducing risks tied to double‑strand breaks and enabling complex cell engineering. Authors argue the approach could simplify manufacturing by avoiding some genomic editing toxicities while enabling multi‑trait enhancement. Translational groups and CDMOs are watching closely: if validated clinically, multiplex epigenetic programming could accelerate next‑generation cell therapies and broaden indications by lowering safety and regulatory hurdles.